DOCSLIB.ORG

Opioids and Glia: Investigating the Mechanisms Through Which Ultra-Low Dose Opioid Antagonists Modulate Opioid Tolerance and Hyperalgesia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioids and Glia: Investigating the Mechanisms Through Which Ultra-Low Dose Opioid Antagonists Modulate Opioid Tolerance and Hyperalgesia OPIOIDS AND GLIA: INVESTIGATING THE MECHANISMS THROUGH WHICH ULTRA-LOW DOSE OPIOID ANTAGONISTS MODULATE OPIOID TOLERANCE AND HYPERALGESIA. by Theresa Alexandra Mattioli A thesis submitted to the Graduate Program in Pharmacology & Toxicology in the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Doctor of Philosophy Queen’s University Kingston, Ontario, Canada (April, 2013) Copyright © Theresa Alexandra Mattioli, 2013 Abstract Ultra-low doses (ULD) of the opioid receptor antagonists, naloxone and naltrexone, augment the analgesic actions of morphine, block the induction of tolerance, and reverse established tolerance by an unknown mechanism. Preclinical studies demonstrate that chronic morphine administration induces spinal gliosis and that inhibition of gliosis prevents the development of analgesic tolerance to opioids. Thus, this thesis investigated the inhibition of spinal gliosis as a mechanism by which ULD antagonists attenuate analgesic tolerance and opioid-induced hyperalgesia. Immune cell activation is implicated in the etiology of morphine tolerance and intrathecal catheterization, a technique commonly used to study the spinal effects of drugs, causes profound gliosis. Thus, the first study investigated the effects of catheter-induced gliosis on acute and chronic morphine analgesic tolerance. Catheterization-induced gliosis did not alter antinociceptive responses to acute intrathecal morphine; however, tolerance to chronic morphine was exacerbated in catheterized rats compared to sham and surgery-naïve controls. The potentiation of analgesic tolerance to chronic morphine by spinal gliosis provided evidence that glia modulate opioid analgesia; therefore, inhibition of opioid-induced activation of glia was explored as a potential mechanism by which ULD antagonists prevent tolerance. The second series of experiments reported morphine-induced activation of spinal microglia and astrocytes was blocked by co-administering ULD naltrexone with morphine. These findings prompted us to elucidate the specific molecular target through which ULD antagonists attenuate opioid analgesia. Activation of glial Toll-like receptor 4 (TLR4) induces gliosis and may contribute to analgesic tolerance and/or morphine-induced hyperalgesia (MIH). Antagonism of TLR4 by the opioid receptor-inactive (+) stereoisomer of naloxone was identified as a potential mechanism by which ULD antagonists modulate opioid analgesia. Tolerance and MIH developed in mice ii expressing non-functional TLR4 and in wildtype controls. Analgesic tolerance was stereoselectively blocked by ULD (-)naloxone, whereas MIH was blocked by both naloxone enantiomers. Collectively, these studies demonstrate analgesic tolerance and MIH occur through distinct mechanisms. ULD naloxone attenuates analgesic tolerance likely via an opioid receptor- mediated mechanism that is TLR4-independent. ULD antagonists do not attenuate tolerance via inhibition of spinal gliosis as hypothesized. In contrast, ULD antagonists prevent MIH by inhibiting opioid-induced gliosis in an opioid receptor- and TLR4-independent manner. iii Co-Authorship The research upon which this thesis is based was conducted by Theresa Alexandra Mattioli under the supervision of Dr. Catherine M. Cahill and Dr. Brian Milne. Dr. Catherine M. Cahill performed the implantation of intrathecal catheters used in Chapter 2 and Ms. Maaja Sutak provided spinal tissue used to in the immunohistochemical assay in Chapter 2. Theresa Alexandra Mattioli contributed immunohistochemical (Fig. 8c) and behavioural data (Fig. 8k) and analyzed this data in Chapter 4. Dr. Francesco Ferrini and Dr. Tuan Trang were responsible for the conduct and analysis of all other experiments in Chapter 4 and preparation of the final manuscript based on data in this chapter. Graham Skelhorne-Gross isolated RNA and performed qRT-PCR analysis of spinal tissue in Chapter 5. Ms. Lihua Xue provided technical support throughout the thesis project. iv Acknowledgements I would like to thank the many people who have supported me throughout this journey. Firstly, to my parents, I would like to thank you for always believing in me and encouraging me to follow my dreams. Your unwavering love and support, and of course the numerous donations to my ‘grocery fund,’ have helped me through a number of challenges. Thank you for teaching me to persevere through the hard times and celebrate my accomplishments. To my siblings, Justin and Jackie, you have always been a source of balance in my life. Justin, you never fail to put a smile on my face even on the toughest days. I am inspired by your spontaneous and carefree spirit, and have learned that the only limitations are those we impose on ourselves. Jax, you’re my best friend, my confidant, and my role model. You’ve always been there for me, whether the voice of reason, getting me out of trouble, or joining me in mischief, I could not ask for a better sister. Thank you for always seeing the best in me and helping me to see obstacles as challenges to be embraced rather than impossibilities. To my closest friends, Alana, Julie, Maaike and Megan, your support over the years has been instrumental to my achievements. Thank you for enabling me to keep perspective, to share a laugh or a tear, and always bringing joy to my life. Many thanks to my thesis committee and the members of the Pharmacology and Toxicology program for their ongoing support and encouragement. Special thanks to Dr. Khem Jhamandas for your valuable insight and guidance throughout this project. Your willingness to share your passion and wisdom has been both infectious and engaging. I would also like to thank the other members of the Cahill lab for all of the laughs, dance parties, and assistance throughout the years. I am very grateful to all of you and will cherish the memories of our years together. To my supervisors, Dr. Catherine Cahill and Dr. Brian Milne, I would like to express my sincere gratitude for your leadership and direction throughout my studies. Cathy, your endless patience, encouragement and advice have been invaluable. You are not only an outstanding academic mentor but also an exceptional role model. You have taught me that it is possible to have it all. Brian, your optimism and fresh perspective were always appreciated, particularly during overwhelming and challenging times. I am excited to start the next chapter of my life and feel well prepared for whatever lies ahead thanks to my supervisors who have certainly gone above and beyond. v Table of Contents Abstract ............................................................................................................................................ ii Co-Authorship ................................................................................................................................ iv Acknowledgements .......................................................................................................................... v List of Figures……………………………………………………………………………………...x List of Tables……………………………………………………………………………………..xii List of Abbreviations…………………………………………………………………………….xiii CHAPTER 1: INTRODUCTION .................................................................................................... 1 1.1.1 Social and Economic Impact of Chronic Pain ......................................................... 1 1.2 Opioid Analgesics ............................................................................................................ 2 1.3 Opioid Tolerance ............................................................................................................. 6 1.3.1 Mechanisms of Opioid Tolerance ............................................................................ 8 1.3.2 Bimodal Theory of Tolerance .................................................................................. 9 1.3.3 Involvement of Spinal Glia in Tolerance ............................................................... 11 1.3.3.1 Glial Activation .................................................................................................. 11 1.3.3.2 Opioid-Induced Glial Activation ....................................................................... 11 1.3.3.3 Gliosis and Opioid Tolerance ............................................................................ 12 1.3.3.4 Inhibition of Gliosis Augments Opioid Tolerance ............................................. 13 1.3.4 TLR4-Induced Gliosis............................................................................................ 14 1.3.4.1 TLR4 Structure & Signaling .............................................................................. 15 1.3.4.2 TLR4 and Opioids .............................................................................................. 17 1.4 ULD Antagonists Attenuate Opioid Tolerance & Hyperalgesia .................................... 18 1.4.1 ULD Antagonists and the Bimodal Theory ........................................................... 18 1.4.2 ULD Antagonists and Filamin A Hypothesis ........................................................ 18 1.4.3 ULD Antagonists and Gliosis ................................................................................ 19 1.5 Research Statement and Objectives ............................................................................... 20 CHAPTER 2: INTRATHECAL CATHETERIZATION INFLUENCES TOLERANCE TO CHRONIC MORPHINE IN RATS ..............................................................................................
Load more

Recommended publications
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Opioid Receptors in Immune and Glial Cells—Implications for Pain Control
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Repository of the Freie Universität Berlin REVIEW published: 04 March 2020 doi: 10.3389/fimmu.2020.00300 Opioid Receptors in Immune and Glial Cells—Implications for Pain Control Halina Machelska* and Melih Ö. Celik Department of Experimental Anesthesiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany Opioid receptors comprise µ (MOP), δ (DOP), κ (KOP), and nociceptin/orphanin FQ (NOP) receptors. Opioids are agonists of MOP, DOP, and KOP receptors, whereas nociceptin/orphanin FQ (N/OFQ) is an agonist of NOP receptors. Activation of all four opioid receptors in neurons can induce analgesia in animal models, but the most clinically relevant are MOP receptor agonists (e.g., morphine, fentanyl). Opioids can also affect the function of immune cells, and their actions in relation to immunosuppression and infections have been widely discussed. Here, we analyze the expression and the role of opioid receptors in peripheral immune cells and glia in the modulation of pain. All four opioid receptors have been identified at the mRNA and protein levels in Edited by: immune cells (lymphocytes, granulocytes, monocytes, macrophages) in humans, rhesus Sabita Roy, monkeys, rats or mice. Activation of leukocyte MOP, DOP, and KOP receptors was University of Miami, United States recently reported to attenuate pain after nerve injury in mice. This involved intracellular Reviewed by: 2+ Lawrence Toll, Ca -regulated release of opioid peptides from immune cells, which subsequently Florida Atlantic University, activated MOP, DOP, and KOP receptors on peripheral neurons.
    [Show full text]
  • Changes in Spinal and Opioid Systems in Mice Deficient in The
    The Journal of Neuroscience, November 1, 2002, 22(21):9210–9220 Changes in Spinal ␦ and ␬ Opioid Systems in Mice Deficient in the A2A Receptor Gene Alexis Bailey,1 Catherine Ledent,2 Mary Kelly,1 Susanna M. O. Hourani,1 and Ian Kitchen1 1Pharmacology Group, School of Biomedical and Life Sciences, University of Surrey, Guildford, Surrey, GU2 7XH United Kingdom, and 2Institut de Recherche Interdisciplinaire en Biologie Humaine et Nucle´ aire, Universite´ Libre de Bruxelles, B-1070 Brussels, Belgium A large body of evidence indicates important interactions be- but not in the brains of the knock-out mice. ␮ and ORL1 receptor tween the adenosine and opioid systems in regulating pain at both expression were not altered significantly. Moreover, a significant ␦ the spinal and supraspinal level. Mice lacking the A2A receptor reduction in -mediated antinociception and a significant increase gene have been developed successfully, and these animals were in ␬-mediated antinociception were detected in mutant mice, shown to be hypoalgesic. To investigate whether there are any whereas ␮-mediated antinociception was unaffected. Comparison compensatory alterations in opioid systems in mutant animals, we of basal nociceptive latencies showed a significant hypoalgesia in have performed quantitative autoradiographic mapping of ␮, ␦, ␬, knock-out mice when tested at 55°C but not at 52°C. The results and opioid receptor-like (ORL1) opioid receptors in the brains and suggest a functional interaction between the spinal ␦ and ␬ opioid spinal cords of wild-type and homozygous A2A receptor knock- and the peripheral adenosine system in the control of pain out mice. In addition, ␮-, ␦-, and ␬Ϫmediated antinociception pathways. using the tail immersion test was tested in wild-type and homozy- ␮ ␦ gous A2A receptor knock-out mice.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Opioid Modulation of Oxytocin Release
    Review Opioid Modulation of Oxytocin Release Mark S. Morris, BA, Edward F. Domino, MD, and Steven E. Domino, MD Analgesia or anesthesia is frequently used for women in of a labor without sufficient cervical dilatation. This labor. A wide range of opioid analgesics with vastly differ- review discusses the scientific basis for opioid modulation ent pharmacokinetics, potencies, and potential side effects of oxytocin release from the posterior pituitary and the can be considered by physicians and midwives for labor- practical implications of this relationship to explain well- ing patients requesting pain relief other than a labor epi- known clinical observations of the effect of morphine on dural. The past 50 years have seen the use of the classic prodromal labor. mu opioid agonist morphine and other opioids diminish markedly for several reasons, including availability of Keywords: endogenous opioids; morphine; meperidine; epidural anesthetics, side effects, formulary restrictions, mu-kappa-delta opioid receptors; oxytocin; and concern for neonatal respiratory depression. Morphine parturition; vasopressin is now primarily used in obstetrics to provide rest and Journal of Clinical Pharmacology, 2010;50:1112-1117 sedation as appropriate for the stressed prodromal stages © 2010 The Author(s) he major hormone involved with parturition to system in modulating oxytocin release, it is of inter- Tstimulate uterine contractions is oxytocin. est to note the use of exogenous mu opioids such as Russell et al1 have reviewed the extensive literature morphine and meperidine in human parturition. on the complexity of the magnocellular oxytocin Different forms of analgesia/anesthesia are needed system. Endogenous opioids mechanisms inhibit for both the benefit of the woman in labor and her oxytocin release as part of the multiple hormones baby.
    [Show full text]
  • Morphine and Heroin Differentially Modulate in Vivo Hippocampal LTP in Opiate-Dependent Rat
    Neuropsychopharmacology (2007) 32, 1738–1749 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org Morphine and Heroin Differentially Modulate In Vivo Hippocampal LTP in Opiate-Dependent Rat 1,3 2,3 2,3 1,3 1 1 2 ,1 Guobin Bao , Lin Kang , Haohong Li , Yuting Li ,LuPu, Peng Xia , Lan Ma and Gang Pei* 1 Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of 2 Sciences, Shanghai, People’s Republic of China; Pharmacology Research Center, Shanghai Medical College and Institutes of Brain Science, Fudan University, Shanghai, People’s Republic of China Addictive drugs have been shown to severely influence many neuronal functions, which are considered as the underlying mechanisms for physiological and psychological dependences. We previously showed that in vivo LTP in rat hippocampal CA1 region is significantly reduced during withdrawal following chronic opiates treatment, and the reduced LTP can be restored by re-exposure of animals to corresponding drugs. Here, we further demonstrated that during opiates withdrawal, the re-exposure of morphine either systemically (subcutaneously) or locally (intracerebroventricularly) could restore the reduced LTP in heroin-dependent rats, but heroin could not restore the reduced LTP, in morphine-dependent rats, indicating differential modulations of hippocampal functions by those two opiates. In contrast, DAMGO, a mu-opioid receptor (MOR) agonist, could restore the reduced LTP, and CTOP, a MOR antagonist, could block the restoration in rats dependent on both opiates, showing that MOR is functional under such conditions. However, the upregulation of hippocampal PKA activity during morphine withdrawal could be suppressed by re-exposure of morphine but not that of heroin, suggesting a likely underlying mechanism of the differential modulation of LTP by two opiates.
    [Show full text]
  • 1 Einleitung 1
    1 EINLEITUNG 1 1 EINLEITUNG In allen Kulturen der Erde spielen bewußtseinsverändernde Drogen eine wichtige Rolle. Seit Jahrtausenden schätzt der Mensch sie als Rausch- und Genußmittel und Bestandteil von Gift- und Heiltränken. Die Halluzinogene der Schamanen, die Pfeilgifte urtümlicher Jäger und das Curare der südamerikanischen Indianer gelten als die ältesten Drogen der Menschheit. Hinweise auf psychoaktive Pflanzenextrakte finden sich schon in archaischen Kulturen vor 12000 Jahren.1,2 Die betäubende und euphorisierende Wirkung des Schlafmohns kannten die Sumerer bereits vor 6000 Jahren. Jedoch bis Anfang des 19. Jahrhunderts war völlig unbekannt, welche Inhaltsstoffe die seit Jahrtausenden geschätzte Wirkung des Opiums in seinen vielfältigen Erscheinungsformen ausmachen. Erst der aus Paderborn stammende Apotheker F.W. Sertürner isolierte und charakterisierte um 1804 den Hauptwirkstoff des Opiums. Aufgrund seiner Wirkung nannte er ihn nach dem griechischen Gott des Schlafes Morpheus, Morphin.3 Zur Behandlung postoperativer Schmerzen sowie zur Linderung tumorbedingter Schmerzzustände sind zentral angreifende Opioidea nach wie vor die Analgetika der ersten Wahl. So wirkungsvoll sie einerseits die Schmerzen lindern, so problematisch ist die Tatsache, daß bei falscher Therapie Abhängigkeit auftreten kann. Aber auch unerwünschte Nebenwirkungen wie Atemdepression, Bradykardie (sinkende Herzfrequenz) oder Obstipation (Verstopfung) stellen ein Problem bei der Behandlung dar, da der a Substanzen wie z. B. Heroin und Codein, welche Bestandteile des Opiums sind oder sich von diesem ableiten, wurden ursprünglich als „Opiate“ bezeichnet. Später wurden alle diese Verbindungen, einschließlich der morphinartigen Analgetika und der analgetisch wirksamen Peptide, unter dem Begriff „Opioide“ zusammen- gefaßt. In dieser Arbeit wird daher der Begriff „Opioide“ verwendet. 1 EINLEITUNG 2 Allgemeinzustand der zumeist schwerst kranken Patienten, die auf eine Opioidtherapie angewiesen sind, sehr schlecht ist.
    [Show full text]
  • Morphine: CYP2D6 Modulation1
    The Journal of Immunology Human White Blood Cells Synthesize Morphine: CYP2D6 Modulation1 Wei Zhu,* Patrick Cadet,* Geert Baggerman,† Kirk J. Mantione,* and George B. Stefano2* Human plasma contains low, but physiologically significant, concentrations of morphine that can increase following trauma or exercise. We now demonstrate that normal, human white blood cells (WBC), specifically polymorphonuclear cells, contain and have the ability to synthesize morphine. We also show that WBC express CYP2D6, an enzyme capable of synthesizing morphine from tyramine, norlaudanosoline, and codeine. Significantly, we also show that morphine can be synthesized by another pathway via L-3,4-dihydroxyphenylalanine (L-DOPA). Finally, we show that WBC release morphine into their environment. These studies provide evidence that 1) the synthesis of morphine by various animal tissues is more widespread than previously thought and now includes human immune cells. 2) Moreover, another pathway for morphine synthesis exists, via L-DOPA, demonstrating an intersection between dopamine and morphine pathways. 3) WBC can release morphine into the environment to regulate them- selves and other cells, suggesting involvement in autocrine signaling since these cells express the ␮3 opiate receptor subtype. The Journal of Immunology, 2005, 175: 7357–7362. he immune-regulatory effects of opioid chemical messen- of plasma morphine include the adrenal gland and/or brain. An- gers are well established (1, 2). Exogenously adminis- other important potential source is white blood cells (WBC;3 leu- T tered opiates are immunosuppressive, inhibiting both cel- kocytes) since morphine is found in plasma constitutively (4). Al- lular and humoral responses via their cytokine-like effects in both though the presence of morphine in human plasma has been the CNS and the periphery (2).
    [Show full text]
  • The Opioid Systems and the Role of Glial Cells in the Effects of Opioids
    Review paper Joanna Mika Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland The opioid systems and the role of glial cells in the effects of opioids Abstract Understanding of the molecular mechanisms in the opioid systems in chronic pain should produce new, more effective methods of the pharmacotherapy of pain. Pharmacological suppression of glial activation in combi- nation with morphine, methadone, fentanyl and buprenorphine may be an important aspect of pain therapy. Long-term use of the classical opioid analgesics in patients with chronic pain processes results in tolerance, and the search of new treatment strategies based on the recognised mechanisms of pain is an important clinical and scientific issue. Key words: opioid peptides, opioid receptors, opioids, morphine, glia, minocycline, pentoxifylline, ibudilast Adv. Pall. Med. 2008; 7: 185–196 The opioid systems certain peptides derived from prodynorphin exert non-opioid effects in addition to opioid effects and for this reason are classified as non-opioid neuropep- Opioid peptides tides [1–8]. In 1997 Zadina et al. discovered new Opioid peptides are derived from three precur- endogenous peptides with a very high affinity and sors: proopiomelanocortin (POMC), proenkephalin selectivity to the MOP opioid receptor. Due to their and prodynorphin. Proopiomelanocortin is the pre- selective effect on the receptor through which mor- cursor of the opioid peptides a-, b- and g-endorphin phine exerts its actions they have been called endo- and of the non-opioid peptides ACTH, a- and b- morphins [9]. While nothing is known about their MSH, CLIP and b-LPH. Of these peptides, the best precursors and genes, their location in the brain- investigated one is b-endorphin, which plays an im- stem, spinal cord and nerve ganglia as well as their portant role in stress, transmission of nociceptive coexistence with the MOP opioid receptor suggest stimuli, hormonal regulation and in the regulation an important role in nociception [10].
    [Show full text]
  • U·M·I University Microfilms International a Bell & Howell Information Company 300 North Zeeb Road
    The cloning, expression and partial characterization of a human delta opioid receptor Item Type text; Dissertation-Reproduction (electronic) Authors Fang, Lei. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 29/09/2021 11:52:35 Link to Item http://hdl.handle.net/10150/186784 INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedtbrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Conditional Gene Knockout Approach to Investigate Delta Opioid Receptor Functions in the Forebrain Paul Chu Sin Chung
    Conditional gene knockout approach to investigate Delta opioid receptor functions in the forebrain Paul Chu Sin Chung To cite this version: Paul Chu Sin Chung. Conditional gene knockout approach to investigate Delta opioid recep- tor functions in the forebrain. Neurobiology. Université de Strasbourg, 2013. English. NNT : 2013STRAJ054. tel-01124236 HAL Id: tel-01124236 https://tel.archives-ouvertes.fr/tel-01124236 Submitted on 6 Mar 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Thèse de Doctorat de l’Université de Strasbourg En Aspects Moléculaires et Cellulaires de la Biologie Mention Neurosciences Présentée par Paul Chu Sin Chung pour l’obtention du grade de Docteur de l’Université de Strasbourg Conditional gene knockout approach to investigate Delta Opioid Receptor functions in the forebrain Thèse soutenue publiquement le 4 octobre 2013 A l’Institut de Génétique et de Biologie Moléculaire et Cellulaire Membres du Jury : Pr Brigitte L. Kieffer Directeur de thèse, Strasbourg Dr Rafael Maldonado Rapporteur externe, Barcelone Pr Andreas Zimmer Rapporteur externe, Bonn Dr Pierre Veinante Rapporteur interne, Strasbourg Dr Ian Kitchen Membre invité, Guildford « Et il n’est rien de plus beau que l’instant qui précède le voyage, l’instant où l’horizon de demain vient nous rendre visite et nous dire ses promesses » Milan Kundera 2 Remerciements… Ce travail de thèse a été effectué sous la direction du professeur Brigitte Kieffer.
    [Show full text]